You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

In Vivo Cell Survival

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), MDS (MDS) Trial in New York (other, radiation, drug)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • Personalized rATG (P-rATG)
  • +7 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 31, 2022

Extramedullary Myeloma Trial in Melbourne (Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent)

Not yet recruiting
  • Extramedullary Myeloma
  • Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Dec 18, 2022

Postoperative Prevention of Tumor Trial in Shanghai (Oral NMN combined with DC cell vaccine)

Not yet recruiting
  • Postoperative Prevention of Tumor
  • Oral NMN combined with DC cell vaccine
  • Shanghai, Shanghai, China
    Shanghai Mengchao Cancer Hospital
Sep 6, 2023

Malignant Ovarian Germ Cell Tumors

Recruiting
  • Fertility Issues
  • observational study
  • Cairo, Egypt
    Department of Obstetrics & Gynecology
Jun 7, 2023

NSCLC Trial in Ghent (Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Dendritic cell immunotherapy
  • +2 more
  • Ghent, Belgium
    Ghent University Hospital
Dec 23, 2022

Hematologic Malignancy Trial in Chengdu (Allogeneic Hematopoietic Stem Cell Transplantation)

Recruiting
  • Hematologic Malignancy
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Mar 12, 2022

Pediatric Hematologic Malignancies Trial in Saint Louis (Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs

Not yet recruiting
  • Pediatric Hematologic Malignancies
  • Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 20, 2022

Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed Trial in Tampa, Columbus (GEM/DOX + TGFBi expanded NK cells)

Recruiting
  • Pediatric Sarcoma, Refractory
  • Pediatric Sarcoma, Relapsed
  • GEM/DOX + TGFBi expanded NK cells
  • Tampa, Florida
  • +1 more
Jan 3, 2023

Following Salvage Surgery for RESidual or reCurrent sqUamous

Not yet recruiting
  • Head and Neck Cancer
  • Molecular Analyses
  • (no location specified)
Mar 28, 2023

Skin Diseases Trial (Exposed to UV)

Not yet recruiting
  • Skin Diseases
  • Exposed to UV
  • (no location specified)
Mar 10, 2023

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia Trial in Columbus (Health Promotion and Education, Medical

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • +11 more
  • Health Promotion and Education
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jul 24, 2023

Disease-free Survival of High-risk Head-neck Cutaneous Squamous

Active, not recruiting
  • Carcinoma, Squamous Cell
  • +5 more
  • Treatment
  • Maastricht, Netherlands
  • +1 more
Apr 26, 2023

3 in Vivo Microscopic Imaging Techniques for Diagnosis of

Completed
  • Basal Cell Carcinoma
  • +5 more
  • Fluorescence-Advanced videodermatoscopy
  • +2 more
  • Saint Etienne, France
    Chu de Saint Etienne
Sep 14, 2023

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Completed
  • Recurrent Childhood Acute Myeloid Leukemia
  • +13 more
    • Miami, Florida
      Nicklaus Children's Hospital
    Jan 18, 2023

    Two-field or Three-field Lymphadenectomy on Overall Survival in

    Completed
    • Esophageal Cancer
    • Since the data were collected retrospectively, there were no interventions
    • Chendu, Sichuan, China
      Sichuan Cancer Hospital
    Nov 18, 2022

    NSCLC Trial in Changsha (Time of immunotherapy infusion)

    Recruiting
    • Non-small Cell Lung Cancer
    • Time of immunotherapy infusion
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Dec 7, 2022

    Renal Cell Carcinoma, Neoadjuvant Trial (Axitinib plus Toripalimab, radical nephrectomy)

    Not yet recruiting
    • Renal Cell Carcinoma
    • Neoadjuvant
    • Axitinib plus Toripalimab
    • radical nephrectomy
    • (no location specified)
    Feb 12, 2023

    Patients Who Received Gene-Modified Cell Therapy

    Enrolling by invitation
    • Long-term Follow-up
    • Gene-Modified Cell Therapy
    • Philadelphia, Pennsylvania
      Abramson Cancer Center Clinical Research Unit, University of Pen
    Jul 21, 2022

    Colon Cancer Stage I Trial in Taoyuan (Magicell-NK contains NK cells suspended in 100 mL normal saline)

    Recruiting
    • Colon Cancer Stage I
    • Magicell-NK contains NK cells suspended in 100 mL normal saline
    • Taoyuan, Taiwan
      Chang Gung Memorial Hospital, Linkou
    Sep 28, 2022

    NSCLC Trial in Jette (68GaNOTA-Anti-MMR-VHH2)

    Recruiting
    • Non-small Cell Lung Cancer
    • Jette, Brussel, Belgium
      Universitair Ziekenhuis Brussel
    Jun 27, 2023

    Nasal Vestibule Carcinoma, Rhinectomy, Nasal Vestibule Trial in France, Italy, United Kingdom (Rhinectomy)

    Recruiting
    • Nasal Vestibule Carcinoma
    • +3 more
    • Rhinectomy
    • Toulouse, Touluse, France
    • +5 more
    Jan 11, 2023

    Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

    Active, not recruiting
    • Sickle Cell Disease
    • DREPAGLOBE drug product
    • Paris, France
      Department of Biotherapy, Necker-Enfants Malades Hospital
    Sep 26, 2022

    Sickle Cell Disease Trial in Atlanta (Biotin Labeled Red Blood Cells)

    Recruiting
    • Sickle Cell Disease
    • Biotin Labeled Red Blood Cells
    • Atlanta, Georgia
    • +2 more
    Nov 1, 2021

    RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL

    Recruiting
    • the Records of Esophageal Cancer
    • Since the data were collected retrospectively, there were no interventions
    • Chendu, Sichuan, China
      Sichuan Cancer Hospital
    Oct 24, 2022

    Nomogram Predicting Survival in Chinese SCLC Patients

    Completed
    • Small Cell Lung Cancer
    • initial chemotherapy response
    • (no location specified)
    Jan 8, 2023